Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial.
Brugaletta S, Gomez-Lara J, Serruys PW, Farooq V, van Geuns RJ, Thuesen L, Dudek D, Koolen J, Chevalier B, McClean D, Windecker S, Smits PC, de Bruyne B, Whitbourn R, Meredith I, van Domburg RT, Sihan K, de Winter S, Veldhof S, Miquel-Hebert K, Rapoza R, Garcia-Garcia HM, Ormiston JA, Bruining N.
Brugaletta S, et al.
JACC Cardiovasc Interv. 2011 Dec;4(12):1281-9. doi: 10.1016/j.jcin.2011.08.014.
JACC Cardiovasc Interv. 2011.
PMID: 22192369
Free article.
Clinical Trial.